Bactolife Raises €30 Million to Launch Binding Proteins for Gut Health in US and Global Markets
Bactolife has secured over €30 million in its Series B funding round to launch its Binding Proteins aimed at promoting gut health by neutralizing harmful metabolites. The Danish biotech firm plans to enter the US market in 2026 and expand into Europe and Asia, with the investment supporting product launches, manufacturing scale-up, and clinical studies. Led by Cross Border Impact Ventures and EIFO, the funding will also facilitate the preparation of food safety dossiers for regulatory approval in the US and Europe.
Theia Market Signal Identification - AI Assisted
Bactolife has raised over €30 million (US$35.1 million) in its Series B investment round to commercialize its Binding Proteins, designed to maintain gut health by neutralizing undesired metabolites. The Danish biotech company plans to enter the US market in 2026 and expand into Europe, Asia, and low- and middle-income regions.
The funding will support the launch of its first human health products under the brand Helm, scale manufacturing, and execute a human study program in the US, EU, and Asia. The investment was led by Cross Border Impact Ventures and EIFO, with participation from existing investors Novo Holdings and Athos.
Bactolife's proteins are produced through precision fermentation and aim to provide a proactive defense against gut dysbiosis. The company is also preparing food safety dossiers for the US and Europe.
Comments